ArticleBMJ medicine2026
Developing a new albuminuria-free risk prediction equation for kidney failure in patients with chronic kidney disease: retrospective cohort study.
Article in BMJ medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting kidney failure risk without albuminuria: implications in chronic kidney disease.BMJ medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop new risk prediction equations for kidney failure in patients with chronic kidney disease who do not require data for the urine albumin to creatinine ratio. Design: Retrospective cohort study. Setting: Stockholm Creatinine Measurements (SCREAM) database of routinely collected electronic healthcare records in primary and outpatient care from the region of Stockholm, Sweden. Participants: 116 158 adults with chronic kidney disease stages 3-4, defined by two estimated glomerular filtration rate (eGFR) results of <60 to ≥15 mL/min/1.73 m², at least 90 days apart, with no intermediate eGFR value ≥60 mL/min/1.73 m², between 1 January 2010 to 31 December 2018. Main outcome measure: Kidney failure, defined as starting kidney replacement therapy, recorded within five years of the index date. Results: Based on temporal split sample validation, development and validation cohorts included 85 012 patients (736 kidney replacement therapy events) and 28 338 patients (114 kidney replacement therapy events), respectively. After Cox regression with automated backwards selection, the final model included 10 predictors (in order of significance): eGFR, age, diabetes, sex, atrial fibrillation, antihypertensive drugs, peripheral artery disease, reduction in eGFR slope, acute kidney injury, and hypertension. Model discrimination was excellent in both the development cohort (C statistic 0.941, 95% confidence interval (CI) 0.932 to 0.951) and validation cohort (C statistic 0.944, 0.923 to 0.965). In 26 229 patients with data for the urine albumin to creatinine ratio, the four variable kidney failure risk equation (KFRE) showed marginal improvement in discrimination over our new equation (C statistic 0.950, 95% CI 0.942 to 0.958 for KFRE Conclusions: The findings of the study indicate that predicting the risk of kidney failure with high accuracy in a general population of patients with chronic kidney disease is possible based on data that are routinely available, without requiring data for the urine albumin to creatinine ratio.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.